Working to Eradicate Gynecologic Cancers

Kathleen N. Moore, MD

Associate Professor
The University of Oklahoma
800 NE 10th St
Suite 5050
Oklahoma City, OK
USA 73104


Biographical Sketch:
Kathleen Moore is assistant professor of gyn oncology at the university of oklahoma where she serves as associate fellowship director and associate director of phase I clinical trials. She holds the Mai Eager Anderson Chair in Cancer Clinical Trials and serves and GOG Co-PI for the University of Oklahoma.

Papers:
12 - Focused Plenary Operative outcomes among a geriatric population of endometrial cancer patients: an ancillary data analysis of Gynecologic Oncology Group study LAP2 46 - Featured Poster Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced-stage serous ovarian or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study 76 - Focused Plenary Complications and surgical staging of endometrial cancer with respect to obesity: a Gynecologic Oncology Group LAP2 ancillary data study 94 - Featured Poster Impact of age on tolerance of chemoradiation and survival for patients with local regionally advanced cervical cancer: a pooled analysis of Gynecologic Oncology Group (GOG) phase III trials 120 - Featured Poster The influence of obesity on disease characteristics and survival among patients with epithelial ovarian cancer 164 - Poster Session A Adenocarcinoma indicates more favorable prognosis with cervix cancer 224 - Poster Session A Characterization of primary platinum resistance in an era of biologic agents and novel chemotherapeutic design 240 - Poster Session A Venous thromboembolism carries a particularly grave prognosis with epithelial ovarian cancer 251 - Poster Session A Acquired platinum resistance among women with high-grade serous epithelial ovarian cancer 367 - Poster Session B Analysis of patients referred to an academic gynecologic oncology clinic with an OVA1 test 426 - Poster Session B The effect of age on completion of prescribed chemoradiation among patients with cervix cancer 431 - Poster Session B Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC) 437 - Poster Session B The impact of obesity on pathologic features and survival with endometrial cancer: a Gynecologic Oncology Group (GOG) LAP2 ancillary data study Moderator Introductions Peri-Operative Considerations in the Elderly Patient with Ovarian Cancer Lecturette: The TCGA Concept